BIO-key International
BKYI
6 hedge funds and large institutions have $203K invested in BIO-key International in 2019 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 0 closing their positions.
20% more funds holding
Funds holding: 5 → 6 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
39% less capital invested
Capital invested by funds: $331K → $203K (-$128K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$64.3K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$15.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.47K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.74K |
BKYI Hedge Fund Activity: Q3 2019 in Review
6 of the 4,573 institutional investors tracked by Wall St. Rank reported a position in BIO-key International (BKYI) for Q3 2019, worth a combined $203K — down 39% from $331K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new BKYI positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $64.3K. The largest seller was Commonwealth Equity Services, cutting an estimated $15.1K.
- 6 institutional investors held BIO-key International (BKYI) as of Q3 2019, up from 5 in Q2 2019.
- Funds reported $203K of BIO-key International stock for Q3 2019, down 39% quarter-over-quarter.
- 1 fund opened new BIO-key International positions in Q3 2019 and 0 closed out, a net change of +1 holder.
- The largest BIO-key International buyer in Q3 2019 was Citadel Advisors, an estimated $64.3K added.
- The largest BIO-key International seller in Q3 2019 was Commonwealth Equity Services, an estimated $15.1K sold.
Based on aggregated 13F filings for Q3 2019.